TuHURA Biosciences, Inc./NV Earnings Per Share Disclosure
Note 4—Net loss per share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows:
|
|
Years Ended December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Numerator: |
|
|
|
|
|
|
||
Net loss attributable to common stockholders |
|
$ |
(30,060,333 |
) |
|
$ |
(22,649,572 |
) |
Denominator: |
|
|
|
|
|
|
||
Weighted-average common shares outstanding - basic and diluted |
|
|
47,927,196 |
|
|
|
18,662,690 |
|
Net loss per share attributable to common shareholders - basic and diluted |
|
$ |
(0.63 |
) |
|
$ |
(1.21 |
) |
Common stock warrants in the amount of 297,029 issued to our financial advisor, H.C. Wainwright & Co., LLC, were not outstanding as common shares as of December 31, 2025 and 2024, however included in the weighted-average common shares outstanding – basic and diluted as if they were considered outstanding.
The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. For the years ended December 31, 2025 and 2024, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period because including them would have had an anti-dilutive effect:
|
|
As of December 31, |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Stock options issued and outstanding |
|
|
18,031,425 |
|
|
|
6,403,818 |
|
Unvested restricted stock units |
|
|
57 |
|
|
|
114 |
|
Warrants |
|
|
23,644,268 |
|
|
|
10,609,855 |
|
Total |
|
|
41,675,750 |
|
|
|
17,013,787 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 31, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.